Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Certara (CERT)
NASDAQ:CERT
Holding CERT?
Track your performance easily
CERT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.41 - $19.87
Previous Close$10.71
Volume3.24M
Average Volume (3M)1.23M
Market Cap
$1.70B
Enterprise Value$1.77B
Total Cash (Recent Filing)$233.02M
Total Debt (Recent Filing)$306.47M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Feb 27, 2025EPS Estimate
$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding160,974,813
10 Day Avg. Volume1,286,174
30 Day Avg. Volume1,231,017
Standard Deviation0.16
R-Squared0.20
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.64
Price to Sales (P/S)4.56
Price to Cash Flow (P/CF)25.00
P/FCF Ratio37.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.75
Enterprise Value/Gross Profit8.31
Enterprise Value/Ebitda35.66
Forecast
1Y Price Target
$13.25Price Target Upside23.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Certara News
PremiumCompany Announcements
Certara, Inc. Reports Q3 2024 Financial Growth
Bulls Say, Bears Say
Bulls Say
Biosimulation PerformanceCertara is the market leader in PBPK modeling, and there is further expansion opportunity driven by regulatory efforts and efficiency opportunities for biopharma.
Market PositionThe company is uniquely positioned to drive further adoption of biosimulation in drug development and cross-sell related software.
Software GrowthManagement highlighted plans to create a fourth software pillar in the Certara suite of offerings, combining its D360 product with Chemaxon to create a tool for customers to use biosimulation to select and optimize molecules.
Bears Say
Business StrategyManagement announced its regulatory services business is under strategic review, noting the business growth profile has diverged from the core biosimulation business and the customer base has less overlap.
Financial PerformanceRevenue now seen at $380-385M, down from $385-400M, with a downward organic adjustment related to regulatory services.
Market EnvironmentManagement continues to expect a challenged end-market environment heading into next year.
---
Ownership Overview
2.26% Insiders
22.00% Mutual Funds
34.22% Other Institutional Investors
25.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CERT FAQ
What was Certara’s price range in the past 12 months?
Certara lowest stock price was $9.41 and its highest was $19.87 in the past 12 months.
What is Certara’s market cap?
Currently, no data Available
When is Certara’s upcoming earnings report date?
Certara’s upcoming earnings report date is Feb 27, 2025 which is in 67 days.
How were Certara’s earnings last quarter?
Certara released its earnings results on Nov 06, 2024. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.108 by $0.022.
Is Certara overvalued?
According to Wall Street analysts Certara’s price is currently Undervalued.
Does Certara pay dividends?
Certara does not currently pay dividends.
What is Certara’s EPS estimate?
Certara’s EPS estimate is $0.12.
How many shares outstanding does Certara have?
Certara has 160,987,730 shares outstanding.
What happened to Certara’s price movement after its last earnings report?
Certara reported an EPS of $0.13 in its last earnings report, beating expectations of $0.108. Following the earnings report the stock price went up 0.733%.
Which hedge fund is a major shareholder of Certara?
Among the largest hedge funds holding Certara’s share is Bridgewater Associates, LP. It holds Certara’s shares valued at 923K.
---
Certara Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.25 (23.72% Upside)
$13.25 (23.72% Upside)
Blogger Sentiment
Bullish
CERT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 99.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.48%
12-Months-Change
Fundamentals
Return on Equity
-2.95%
Trailing 12-Months
Asset Growth
1.07%
Trailing 12-Months
Company Description
Certara
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
---
CERT Company Deck
---
CERT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights Certara's strong revenue growth, successful acquisitions, and advancements in biosimulation and AI, which are driving demand and bookings. However, challenges in the regulatory services market and lengthened decision-making processes among larger customers have led to a cautious outlook and guidance revision.Read More>---
CERT Stock 12 Month Forecast
Average Price Target
$13.25
▲(23.72% Upside)
Technical Analysis
Recursion Pharmaceuticals
―
Veeva Systems
―
Ultragenyx Pharmaceutical
―
Exact Sciences
―
Best Analysts Covering CERT
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-15.94%
reiterated a buy rating 3 months ago
Copying Michael Ryskin's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -15.94% per trade.
---